CERo Therapeutics Enters $2.1M Amended Convertible Promissory Note with SRX Global
On July 14, 2026, CERo Therapeutics Holdings, Inc. entered into a second amended and restated promissory note with SRX Global Inc. (formerly SRx Health Solutions, Inc.). The agreement allows the Company to borrow up to a maximum aggregate principal amount of $2,085,200. As of the filing date, the full amount has been funded across three tranches: $750,000 on May 23, 2026; $663,600 on June 23, 2026; and $671,600 on July 14, 2026. The note bears an annual interest rate of 10% and matures on May 28, 2027. It is convertible into CERoβs common stock at the Lender's option at a conversion price equal to the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the 20 days preceding a conversion request, subject to a 4.99% beneficial ownership limitation. CERo has committed to filing a registration statement with the SEC to cover the resale of the common stock issuable upon conversion. The proceeds are intended for purposes specified in the confidential schedules of the agreement.